JP2021527711A5 - - Google Patents
Info
- Publication number
- JP2021527711A5 JP2021527711A5 JP2021519528A JP2021519528A JP2021527711A5 JP 2021527711 A5 JP2021527711 A5 JP 2021527711A5 JP 2021519528 A JP2021519528 A JP 2021519528A JP 2021519528 A JP2021519528 A JP 2021519528A JP 2021527711 A5 JP2021527711 A5 JP 2021527711A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- disease
- pabra
- Prior art date
Links
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685249P | 2018-06-14 | 2018-06-14 | |
| US201862685246P | 2018-06-14 | 2018-06-14 | |
| US201862685247P | 2018-06-14 | 2018-06-14 | |
| US62/685,246 | 2018-06-14 | ||
| US62/685,247 | 2018-06-14 | ||
| US62/685,249 | 2018-06-14 | ||
| US201862686660P | 2018-06-18 | 2018-06-18 | |
| US201862686663P | 2018-06-18 | 2018-06-18 | |
| US201862686658P | 2018-06-18 | 2018-06-18 | |
| US62/686,663 | 2018-06-18 | ||
| US62/686,658 | 2018-06-18 | ||
| US62/686,660 | 2018-06-18 | ||
| US201962825670P | 2019-03-28 | 2019-03-28 | |
| US201962825702P | 2019-03-28 | 2019-03-28 | |
| US201962825571P | 2019-03-28 | 2019-03-28 | |
| US201962825675P | 2019-03-28 | 2019-03-28 | |
| US62/825,571 | 2019-03-28 | ||
| US62/825,670 | 2019-03-28 | ||
| US62/825,675 | 2019-03-28 | ||
| US62/825,702 | 2019-03-28 | ||
| PCT/US2019/037358 WO2019241736A1 (en) | 2018-06-14 | 2019-06-14 | Methods for improving neurological diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527711A JP2021527711A (ja) | 2021-10-14 |
| JPWO2019241736A5 JPWO2019241736A5 (https=) | 2022-06-08 |
| JP2021527711A5 true JP2021527711A5 (https=) | 2022-06-08 |
Family
ID=68842342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519528A Pending JP2021527711A (ja) | 2018-06-14 | 2019-06-14 | 神経系疾患および障害の改善のための方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3806847A4 (https=) |
| JP (1) | JP2021527711A (https=) |
| AU (1) | AU2019287771A1 (https=) |
| CA (1) | CA3100848A1 (https=) |
| WO (1) | WO2019241736A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4208159A4 (en) * | 2020-09-01 | 2024-09-25 | Curasen Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE RELIEF OF NEUROLOGICAL CONDITIONS AND DISORDERS |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
| US20040248984A1 (en) * | 2001-08-29 | 2004-12-09 | Josef Krieglstein | Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases |
| WO2011133226A2 (en) * | 2010-04-22 | 2011-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same |
| US9265735B2 (en) * | 2010-11-30 | 2016-02-23 | New York University | Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof |
| US9320724B2 (en) * | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| KR20160026897A (ko) * | 2013-06-27 | 2016-03-09 | 세다르스-신나이 메디칼 센터 | 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제 |
-
2019
- 2019-06-14 WO PCT/US2019/037358 patent/WO2019241736A1/en not_active Ceased
- 2019-06-14 CA CA3100848A patent/CA3100848A1/en active Pending
- 2019-06-14 EP EP19819477.1A patent/EP3806847A4/en not_active Withdrawn
- 2019-06-14 JP JP2021519528A patent/JP2021527711A/ja active Pending
- 2019-06-14 AU AU2019287771A patent/AU2019287771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527711A5 (https=) | ||
| JP2021527712A5 (https=) | ||
| KR101581289B1 (ko) | 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민 | |
| RU2471781C2 (ru) | Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии | |
| US20130065904A1 (en) | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | |
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| JP2013256526A (ja) | （−）−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
| JP2008520589A5 (https=) | ||
| HUP0300030A2 (en) | Bupropion metabolites and methods of their synthesis and use and pharmaceutical compositions containing them and and their use | |
| JP2011504474A5 (https=) | ||
| JPWO2021127210A5 (https=) | ||
| JPWO2019241736A5 (https=) | ||
| MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
| PT98427A (pt) | Metodo para tratamento de doencas do sistema nervoso central com compostos amino-alcoois heterociclicos | |
| HUP0301551A2 (hu) | 5-HT3 és idegi nikotinsav receptor antagonista 1-amino-alkil-ciklohexán származékok új alkalmazása | |
| JPWO2019241744A5 (https=) | ||
| US7030164B2 (en) | Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof | |
| JP2005511625A5 (https=) | ||
| JPWO2020132474A5 (https=) | ||
| JP2015172059A (ja) | トリプル再取込み阻害剤及びそれらの使用方法 | |
| KR102254542B1 (ko) | 과다운동성 운동 장애의 예방 및/또는 치료에 사용하기 위한 치료제 | |
| JP2019529502A5 (https=) | ||
| JP2012509860A5 (https=) | ||
| AU2012202991B2 (en) | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders | |
| Trivedi | Comparative Study of Efficacy for Bupropion vs. Sertraline (SSRI) in Depression with Parkinson’s Disease |